Efficacy of the Anticancer Agent Cisplatin in the Treatment of Human Cervical Squamous Carcinoma Xenografted in Nude Mice

Abstract

Two human squamous carcinomas of the cervix, established by serial passage in nude mice, are described. The reponse of the tumours to cis-diamminedichloro-platinum (CDDP) was assessed by comparing tumour weights and by histological observations. Tumours treated with CDDP 10 mg/kg/week for 2 weeks regressed significantly and microscopy revealed extensive degeneration. Treatment with CDDP 5 mg/kg/week produced tumour growth retardation and microscopy showed some degenerative changes, however, viable cells, many of which were mitotic, were evident. There was, therefore, a dose-response relationship. The sensitivity of the tumours to CDDP lends support to its use in humans with this malignancy.

Phase I/II study of a short course of weekly cisplatin in patients with advanced solid tumours

“…In vitro studies in human cancer cell lines and clinical trials in several tumour types have suggested a doseresponse relationship for cisplatin (Pillay et al, 1986;Bruckner et al, 1984;Ozols et al, 1985;Ozols, 1989;Gandara et al, 1989;Forastiere et al, 1987). The application of high doses or frequent administration of lower doses of cisplatin is however, hampered by side effects such as severe nausea and vomiting, neurotoxicity and nephrotoxicity.…”

Effects of Platinum-Thymine on Mitosis of Sarcoma-180 Ascites Cells in vitro: Ultrastructural Study

“…One of the major discoveries in cancer therapy has been the use of platinum drugs [1][2][3][4][5][6][7][8][9][10]. Of these, cis-dichlorodiammineplatinum II (cisplatin) has proven to be active against a broad spectrum of tu mor systems [11][12][13][14], As a result of using animal models, analogs with improved antitumor activities and reduced toxicities relative to cis-dichlorodiammineplatinum 1 Supported by MBRS Grant No.…”